Loading...
Neonc Technologies Holdings, Inc.
NTHI•NASDAQ
HealthcareBiotechnology
$7.42
$-0.07(-0.93%)
Neonc Technologies Holdings, Inc. (NTHI) Company Profile & Overview
Explore Neonc Technologies Holdings, Inc.’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.
Neonc Technologies Holdings, Inc. (NTHI) Company Profile & Overview
Neonc Technologies Holdings, Inc. develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.
SectorHealthcare
IndustryBiotechnology
CEODr. Thomas C. Chen M.D., Ph.D.
Contact Information
Company Facts
8 Employees
IPO DateMar 26, 2025
CountryUS
Actively Trading